Despite its well-established anti-tumor function, the NKG2D axis is being carefully considered in immunotherapy as the presence of NKG2D ligands on healthy tissue subject to chronic inflammation raises concerns about possible on-target off-tumor toxicity [22,23,24]. The gene discussed is KLRK1; the disease is neoplasm.